Market Research Logo

Cancer/Tumor Profiling - Global Market Outlook (2016-2022)

Cancer/Tumor Profiling - Global Market Outlook (2016-2022)

According to Stratistics MRC, the Global Cancer/Tumor Profiling market is expected to grow from $23.04 billion in 2015 to reach $78.69 billion by 2022 with a CAGR of 19.2%. Increasing cases of cancer and the need for therapy are the major factors influencing the market growth. Moreover, high investments in R&D, technological developments, and demand for safer medicines are the factors fostering the market growth. However, low awareness among clinicians about options and potential of cancer profiling are the major challenges for this market.

By application, personalized medicines segment leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth is attributed by unique characteristics of this segment in examining and prognosis of cancer disease. North America commands the market due to the presence of leading cancer profiling industry leaders. Asia Pacific is expected to witness huge growth due to raising incidence of cancer in this region.

Some of the key players in global Cancer/Tumor profiling market include Agendia Nv, Biotheranostics, Boreal Genomics, Inc., Caris Life Sciences, Genomic Health, Inc., Illumina, Inc., Life Technologies Corporation, Nanostring Technologies, Neogenomics Laboratories, Oncopath Laboratory, Oxford Gene Technology Ltd, Precision Therapeutics, Inc., Proteome Sciences Plc, Rational Therapeutics, and Ribomed Biotechnologies.

Applications Covered:
Biomarker Discovery
Diagnostics
Personalized Medicine
Prognosis
Research Applications

Technologies Covered:
Fluorescence/Chromogenic In Situ Hybridization
Immunohistochemistry
Microarray
Next-Generation Sequencing
Quantitative PCR

Regions Covered:
North America
US
Canada
Mexico
Europe
Germany
France
Italy
UK
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia
New Zealand
Rest of Asia Pacific
Rest of the World
Middle East
Brazil
Argentina
South Africa
Egypt

What our report offers:
Market share assessments for the regional and country level segments
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Technology Analysis
3.8 Emerging Markets
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cancer/Tumor Profiling Market, By Application
5.1 Introduction
5.2 Biomarker Discovery
5.3 Diagnostics
5.4 Personalized Medicine
5.5 Prognosis
5.6 Research Applications
6 Global Cancer/Tumor Profiling Market, By Technology
6.1 Introduction
6.2 Fluorescence/Chromogenic In Situ Hybridization
6.3 Immunohistochemistry
6.4 Microarray
6.5 Next-Generation Sequencing
6.6 Quantitative PCR
7 Global Cancer/Tumor Profiling Market, By Geography
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.2.6 Rest of Europe
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 Rest of the World
7.4.1 Middle East
7.4.2 Brazil
7.4.3 Argentina
7.4.4 South Africa
7.4.5 Egypt
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Agendia Nv
9.2 Biotheranostics
9.3 Boreal Genomics, Inc.
9.4 Caris Life Sciences
9.5 Genomic Health, Inc.
9.6 Illumina, Inc.
9.7 Life Technologies Corporation
9.8 Nanostring Technologies
9.9 Neogenomics Laboratories
9.10 Oncopath Laboratory
9.11 Oxford Gene Technology Ltd
9.12 Precision Therapeutics, Inc.
9.13 Proteome Sciences Plc
9.14 Rational Therapeutics
9.15 Ribomed Biotechnologies
List of Tables
Table 1 Global Cancer/Tumor Profiling Market, By Region (2013-2022) ($MN)
Table 2 Global Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 3 Global Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 4 Global Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 5 Global Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 6 Global Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 7 Global Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 8 Global Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 9 Global Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 10 Global Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 11 Global Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 12 Global Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 13 Global Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
Table 14 North America Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
Table 15 North America Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 16 North America Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 17 North America Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 18 North America Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 19 North America Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 20 North America Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 21 North America Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 22 North America Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 23 North America Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 24 North America Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 25 North America Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 26 North America Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
Table 27 Europe Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
Table 28 Europe Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 29 Europe Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 30 Europe Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 31 Europe Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 32 Europe Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 33 Europe Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 34 Europe Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 35 Europe Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 36 Europe Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 37 Europe Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 38 Europe Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 39 Europe Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
Table 40 Asia Pacific Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
Table 41 Asia Pacific Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 42 Asia Pacific Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 43 Asia Pacific Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 44 Asia Pacific Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 45 Asia Pacific Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 46 Asia Pacific Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 47 Asia Pacific Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 48 Asia Pacific Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 49 Asia Pacific Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 50 Asia Pacific Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 51 Asia Pacific Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 52 Asia Pacific Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
Table 53 RoW Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
Table 54 RoW Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
Table 55 RoW Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
Table 56 RoW Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
Table 57 RoW Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
Table 58 RoW Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
Table 59 RoW Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
Table 60 RoW Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
Table 61 RoW Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
Table 62 RoW Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
Table 63 RoW Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
Table 64 RoW Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
Table 65 RoW Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report